MarketCapExport financials
Centene Corporation (CNC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Centene Corporation Financial Ratios 2025-2007 | CNC
Brief overview of Centene Corporation's valuation multiples
Ratios are assessed across five available annual reports in the 2020–2024 interval.
Key multiples at the end of the period are P/E 8.86x (median 18.48x), EV/EBITDA 26.39x (median 14.3x), P/S 0.1x (median 0.28x). On average, this basket is 40.1% below its own five-year medians. The market values the business at a discount to recent history.
Earnings yield calculated as 1/P/E is about 11.3%, showing current profit per unit of share price.
Returns on assets and capital are represented by ROE -33.4%, ROA -8.7%, ROCE -38.2%. Current return ratios are negative, materially weakening the fundamental profile.
The cash cycle changed only slightly and ended at 7.4 days.
Overall assessment
Centene Corporation's restrained price comes with modest current quality. Better efficiency is needed for revaluation.
Annual Financial Ratios Centene Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3.1 | 8.9 | 15.9 | 34.9 | 35.7 | 18.5 | 19.9 | 28.2 | 22.6 | 17.8 | 20.8 | 23.4 | 20.0 | 1211.4 | 19.7 | 2.9 | 2.3 | 2.6 | - |
P/S |
0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | 0.2 | 0.3 | 0.4 | 0.3 | 0.3 | 0.4 | 0.1 | 0.0 | 0.1 | - |
EPS |
-13.5 | 6.3 | 5.0 | 2.1 | 2.3 | 3.2 | 3.2 | 2.3 | 2.4 | 1.8 | 3.0 | 2.3 | 1.5 | 0.0 | 2.2 | 1.9 | 1.9 | 1.9 | - |
EV (Enterprise Value) |
59.2 B | 71.2 B | 84.6 B | 82.5 B | 86.4 B | 65.4 B | 42.5 B | 39.9 B | 29.7 B | 20.4 B | 10.8 B | 8.9 B | 4.61 B | 3.2 B | 3.45 B | 985 M | 872 M | -163 M | -269 M |
EBITDA per Share |
-12.9 | 8.46 | 7.77 | 4.78 | 5.35 | 7.61 | 5.59 | 4.28 | 3.93 | 4.41 | 3.43 | 2.38 | 1.59 | 0.324 | 1.24 | 4.29 | 4.23 | 3.86 | - |
EV/EBITDA |
-9.3 | 16.1 | 20.0 | 30.0 | 26.4 | 10.6 | 12.1 | 16.0 | 14.3 | 7.6 | 8.4 | 10.2 | 8.5 | 29.2 | 7.9 | 4.7 | 4.8 | -1.0 | - |
PEG |
0.07 | 0.66 | 0.89 | 4.92 | 5.09 | 0.99 | 0.52 | -7.12 | 0.62 | 0.98 | 0.75 | 0.44 | 0.0 | -12.34 | 1.43 | - | - | - | - |
P/B |
1.0 | 1.1 | 1.7 | 1.7 | 1.8 | 1.3 | 2.1 | 2.3 | 2.7 | 1.7 | 3.4 | 3.6 | 2.7 | 2.4 | 2.3 | 0.3 | 0.3 | - | - |
P/CF |
4.0 | 190.2 | 5.3 | 6.7 | 11.5 | 6.1 | 34.9 | 45.4 | 17.6 | 6.5 | 14.5 | 5.7 | 10.5 | 11.5 | 11.7 | 1.6 | 0.8 | 1.0 | - |
ROE % |
-33.45 | 12.51 | 10.46 | 4.97 | 5.00 | 6.98 | 10.44 | 8.17 | 12.06 | 9.51 | 16.37 | 15.55 | 13.28 | 0.19 | 11.88 | 11.94 | 13.93 | 16.66 | - |
ROA % |
-8.70 | 4.01 | 3.19 | 1.56 | 1.72 | 2.63 | 3.22 | 2.91 | 3.79 | 2.78 | 4.84 | 4.64 | 4.68 | 0.07 | 5.08 | 4.88 | 4.91 | - | - |
ROCE % |
-38.20 | 12.02 | 11.34 | 5.45 | 6.62 | 11.91 | 7.31 | 7.70 | 9.57 | 10.89 | 19.00 | 15.79 | 14.08 | 0.06 | 14.07 | 19.78 | 22.99 | 26.25 | - |
Current Ratio |
1.4 | 1.5 | 1.4 | 1.5 | 1.5 | 1.6 | 1.6 | 1.0 | 0.9 | 1.0 | 1.0 | 1.0 | 1.2 | 1.1 | 1.1 | 1.7 | 1.6 | - | - |
DSO |
- | - | - | - | - | - | 30.5 | 31.3 | 25.7 | 27.8 | 20.5 | 20.1 | 14.4 | 11.1 | 10.8 | - | - | - | - |
DPO |
- | - | - | - | - | - | 23.1 | 28.6 | 35.7 | 39.2 | 17.8 | 18.7 | 14.2 | 8.8 | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | 30.5 | 31.3 | 25.7 | 27.8 | 20.5 | 20.1 | 14.4 | 11.1 | 10.8 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | 7.4 | 2.7 | -10.0 | -11.3 | 2.7 | 1.4 | 0.2 | 2.3 | 10.8 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Centene Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.51 | 2.64 | -0.7400000000000002 | 1.37 | 2.16 | 2.17 | - | 0.87 | 1.93 | 2.05 | -0.1299999999999999 | 1.29 | -0.29 | 1.46 | - | - | - | 1.46 | - | 1 | -0.92 | 1.2 | - | 0.98 | 2.08 | 0.08 | 0.5 | 0.23 | 1.2 | 1.26 | 0.59 | 0.05 | 0.77 | 0.98 | 0.67 | 0.59 | 0.74 | 0.4 | 1.53 | 0.86 | 1 | -0.13 | 0.93 | 0.78 | 0.74 | 0.53 | 0.91 | 0.7 | 0.42 | 0.29 | 0.48 | 0.45 | 0.37 | 0.22 | 0.17 | 0.07 | -0.68 | 0.47 | 0.6 | 0.58 | 0.57 | 0.48 | 0.5 | 0.53 | 0.48 |
EBITDA per Share |
-0.58 | 3.44 | 8.95 | 1.61 | 2.65 | 2.39 | - | 1.7 | 2.46 | 2.54 | 135 | 1.2 | 0.12 | 2.49 | - | - | - | 2.82 | - | 1.27 | -0.39 | 2.43 | - | 3.07 | 4.55 | 0.87 | - | 1.57 | 2.31 | 2.03 | - | 0.96 | 1.8 | 1.85 | - | 3.5 | 3.54 | 1.89 | - | 3.11 | 2.86 | 0.44 | - | 2.22 | 1.9 | 1.31 | - | 1.48 | 1.17 | 0.78 | - | 2.45 | 1.86 | 1.06 | - | 0.43 | -0.26 | 0.99 | - | 1.82 | 1.67 | 1.07 | 0.14 | 1.11 | 0.73 |
ROE % |
5.42 | 10.81 | 10.32 | 13.58 | 15.21 | 15.47 | 11.00 | 10.67 | 11.45 | 6.46 | 4.95 | 8.40 | 7.86 | 6.43 | 3.27 | 3.27 | 3.27 | 5.92 | 2.80 | 5.00 | 7.47 | 9.72 | 7.06 | 8.73 | 7.28 | 6.54 | 10.53 | 11.07 | 10.48 | 9.29 | 8.24 | 9.39 | 12.21 | 13.17 | 12.09 | 13.16 | 12.66 | 11.83 | 9.53 | 10.25 | 12.07 | 13.27 | 16.46 | 17.45 | 17.84 | 16.57 | 15.54 | 13.70 | 12.97 | 13.40 | 13.37 | 10.03 | 6.46 | -0.46 | 0.20 | 2.46 | 5.16 | 11.86 | 11.89 | 13.73 | 14.48 | 14.58 | 5.07 | 3.84 | 3.13 |
ROA % |
1.85 | 3.58 | 3.27 | 4.22 | 4.60 | 4.55 | 3.14 | 3.03 | 3.43 | 1.96 | 1.74 | 2.87 | 2.66 | 2.14 | 1.03 | 1.03 | 1.03 | 2.02 | 1.00 | 1.82 | 2.83 | 3.64 | 2.65 | 3.16 | 2.56 | 2.02 | 3.22 | 3.49 | 3.32 | 3.09 | 2.91 | 3.19 | 4.06 | 4.25 | 3.79 | 4.03 | 3.82 | 3.50 | 2.78 | 3.00 | 3.54 | 3.90 | 4.84 | 5.16 | 5.30 | 4.94 | 4.65 | 4.32 | 4.30 | 4.59 | 4.68 | 3.50 | 2.25 | -0.16 | 0.06 | 1.11 | 2.30 | 4.87 | 5.08 | 4.94 | 5.01 | 4.86 | 1.23 | 1.40 | 1.14 |
ROCE % |
6.33 | 12.80 | 11.28 | 14.61 | 16.88 | 17.18 | 12.92 | 13.63 | 12.36 | 7.04 | 6.65 | 10.55 | 10.84 | 9.71 | 5.06 | 5.06 | 5.06 | 9.06 | 4.45 | 7.79 | 13.56 | 15.90 | 11.90 | 13.30 | 15.08 | 12.71 | 11.98 | 12.36 | 15.44 | 15.26 | 9.80 | 14.76 | 20.78 | 19.81 | 14.86 | 20.66 | 22.09 | 16.04 | 12.54 | 21.02 | 23.24 | 22.82 | 22.48 | 28.68 | 25.53 | 21.52 | 15.54 | 22.35 | 21.72 | 19.60 | 15.59 | 12.69 | 0.97 | -1.01 | -4.22 | 0.97 | 9.78 | 18.87 | 15.28 | 22.80 | 23.74 | 22.91 | 7.52 | 6.14 | 5.07 |
Current Ratio |
1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | - | - | - | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | 1.4 | 1.4 | 1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.8 | 1.8 | 1.8 | 1.8 | 1.6 | 1.6 | 1.6 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Centene Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health care industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Molina Healthcare
MOH
|
$ 214.9 | -2.26 % | $ 11.3 B |  USA |
 |
UnitedHealth Group Inc.
UNH
|
$ 417.0 | -0.54 % | $ 379 B | USA |
 |
Humana
HUM
|
$ 425.42 | -0.46 % | $ 51.2 B | USA |
 |
NovoCure Limited
NVCR
|
$ 15.59 | -0.76 % | $ 1.74 B |  Jersey |
 |
Triple-S Management Corporation
GTS
|
- | 0.28 % | $ 847 M | USA |
 |
Cigna Corporation
CI
|
$ 304.37 | -0.82 % | $ 80.2 B | USA |
 |
CVS Health Corporation
CVS
|
$ 93.45 | -1.34 % | $ 118 B | USA |
 |
Magellan Health, Inc.
MGLN
|
- | -0.19 % | $ 2.49 B | USA |
 |
Anthem
ANTM
|
- | -2.32 % | $ 107 B | USA |